0
Innovation in Pediatric Drugs Act of 2025
3/21/2025, 1:51 PM
Summary of Bill S 705
One of the key provisions of the bill is to encourage the development of more targeted therapies for pediatric cancer. This is important because traditional cancer treatments can be harsh and have serious side effects, especially for children. By focusing on targeted therapies, the hope is that treatments can be more effective and less harmful.
The bill also includes provisions to improve the way clinical trials for pediatric cancer are conducted. This includes requiring the Food and Drug Administration (FDA) to consider the unique needs of children when reviewing new cancer treatments. Additionally, the bill aims to increase collaboration between researchers, healthcare providers, and patient advocacy groups to ensure that the best possible treatments are being developed and made available to children with cancer. Overall, Bill 119 s 705 is a bipartisan effort to improve the way pediatric cancer is researched and treated in the United States. By focusing on molecularly targeted therapies and improving the clinical trial process, the bill aims to give children with cancer better access to effective and less harmful treatments.
Congressional Summary of S 705
Innovation in Pediatric Drugs Act of 2025
This bill expands the Food and Drug Administration’s (FDA’s) authority with respect to research on rare pediatric diseases, including by permitting the FDA to require pediatric studies on certain orphan drugs and to take enforcement action against drug sponsors that fail to satisfy pediatric study requirements.
Specifically, the bill would impose pediatric study requirements on drugs for rare diseases or conditions (i.e., orphan drugs) if the FDA determines that (1) the drug could improve the treatment, diagnosis, or prevention of a disease compared with currently available products for the relevant pediatric population; or (2) there is a need for additional options within the drug’s class or indication. (Under current law, pediatric study requirements generally do not apply to orphan drugs.) The FDA must issue guidance describing how these changes will be implemented, including information on how waivers will be granted.
The bill also permits the FDA to take enforcement action against drug sponsors that fail to comply with pediatric study requirements, if such sponsors demonstrated a lack of due diligence in satisfying the requirements.
Additionally, the bill authorizes the National Institutes of Health to allot a certain amount of funds for priority pediatric research, including research on drugs with no remaining patents on which pediatric studies are needed.
Finally, the Government Accountability Office must report on the bill’s impact on rare disease drug development and on the availability of pediatric information on orphan drugs.
